Drugs / BMN 044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02958202 | Apr → Sep 2016 | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMN 044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958202 ↗ |
| Route | Intravenous | “Weekly intravenous (IV) dosing with 6 mg/kg” NCT02958202 ↗ |